ANAB · Company research
AnaptysBio, Inc. Common Stock (ANAB): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer | GSK received FDA approval for Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The AZUR-1 trial showed 68% of patients achieved sustained clinical complete responses at 12 months without surgery, with no disease recurrences reported among responders after median follow-up of over 2 years. The approval could help eligible patients avoid chemotherapy, radiation, and surgery. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| AnaptysBio, Inc. (ANAB) Stock Price, News, Quote & History - Yahoo! Finance Canada | AnaptysBio, Inc. (ANAB) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| AnaptysBio: Fully Valued — With Major Litigation Uncertainty (NASDAQ:ANAB) - Seeking Alpha | AnaptysBio: Fully Valued — With Major Litigation Uncertainty (NASDAQ:ANAB) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise - Yahoo Finance | AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| AnaptysBio (ANAB) Edges Lower to $48.53 as Shares Consolidate Below Resistance - Fast Moving Stocks - https://www.siam.in/ | AnaptysBio (ANAB) Edges Lower to $48.53 as Shares Consolidate Below Resistance - Fast Moving Stocks https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 4, 2026 | neutral | 0 | 0.6 |
| AnaptysBio (NASDAQ:ANAB) Downgraded by Wall Street Zen to Hold - MarketBeat | AnaptysBio (NASDAQ:ANAB) Downgraded by Wall Street Zen to Hold MarketBeat | View source ↗ | MarketBeat | Oct 4, 2026 | neutral | 0 | 0.6 |
| After an $18.03-per-share option exercise, AnaptysBio (ANAB) director sells 5,000 shares. - Stock Titan | After an $18.03-per-share option exercise, AnaptysBio (ANAB) director sells 5,000 shares. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| AnaptysBio (NASDAQ:ANAB) Director Sells 5,000 Shares of Company Stock - MarketBeat | AnaptysBio (NASDAQ:ANAB) Director Sells 5,000 Shares of Company Stock MarketBeat | View source ↗ | MarketBeat | Oct 2, 2026 | neutral | 0 | 0.6 |
| Director Hollings C. Renton plans to sell 5,000 AnaptysBio (ANAB) shares valued at about $249K. - Stock Titan | Director Hollings C. Renton plans to sell 5,000 AnaptysBio (ANAB) shares valued at about $249K. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance - Yahoo Finance | AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance Yahoo Finance | View source ↗ | Yahoo Finance | Sep 26, 2026 | neutral | 0 | 0.6 |
| AnaptysBio (NASDAQ:ANAB) Stock Bumped Up to Buy by Wall Street Zen - MarketBeat | AnaptysBio (NASDAQ:ANAB) Stock Bumped Up to Buy by Wall Street Zen MarketBeat | View source ↗ | MarketBeat | Sep 26, 2026 | neutral | 0 | 0.6 |
| Leerink Partners Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat | Leerink Partners Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price MarketBeat | View source ↗ | MarketBeat | Sep 23, 2026 | neutral | 0 | 0.6 |
| ANAB: AnaptysBio Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | ANAB: AnaptysBio Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Sep 21, 2026 | neutral | 0 | 0.6 |
| AnaptysBio (ANAB) director adds shares as RSUs vest - Stock Titan | AnaptysBio (ANAB) director adds shares as RSUs vest Stock Titan | View source ↗ | Stock Titan | Sep 17, 2026 | neutral | 0 | 0.6 |
| AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup - ChartMill | AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup ChartMill | View source ↗ | ChartMill | Aug 19, 2026 | neutral | 0 | 0.6 |
| AnaptysBio Stock: The Royalty Waterfall Is About To Reverse (NASDAQ:ANAB) - Seeking Alpha | AnaptysBio Stock: The Royalty Waterfall Is About To Reverse (NASDAQ:ANAB) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 29, 2026 | neutral | 0 | 0.6 |
| What Makes AnaptysBio (ANAB) an Investment Bet? - Yahoo Finance | What Makes AnaptysBio (ANAB) an Investment Bet? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 14, 2026 | neutral | 0 | 0.6 |
| ANAB Forecast — Price Target — Prediction for 2027 - TradingView | ANAB Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| $ANAB stock is down 26% today. Here's what we see in our data. - Quiver Quantitative | $ANAB stock is down 26% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 20, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.